Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Free Cash Flow: 2013-2025

Historic Free Cash Flow for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to -$56.7 million.

  • Ocular Therapeutix's Free Cash Flow fell 54.76% to -$56.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.4 million, marking a year-over-year decrease of 67.25%. This contributed to the annual value of -$136.0 million for FY2024, which is 78.15% down from last year.
  • Latest data reveals that Ocular Therapeutix reported Free Cash Flow of -$56.7 million as of Q3 2025, which was down 0.42% from -$56.5 million recorded in Q2 2025.
  • Over the past 5 years, Ocular Therapeutix's Free Cash Flow peaked at -$8.0 million during Q3 2023, and registered a low of -$56.7 million during Q3 2025.
  • In the last 3 years, Ocular Therapeutix's Free Cash Flow had a median value of -$34.3 million in 2024 and averaged -$33.8 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first spiked by 43.67% in 2022, then slumped by 358.62% in 2024.
  • Quarterly analysis of 5 years shows Ocular Therapeutix's Free Cash Flow stood at -$15.8 million in 2021, then decreased by 21.06% to -$19.1 million in 2022, then declined by 19.91% to -$22.9 million in 2023, then tumbled by 72.96% to -$39.6 million in 2024, then plummeted by 54.76% to -$56.7 million in 2025.
  • Its Free Cash Flow stands at -$56.7 million for Q3 2025, versus -$56.5 million for Q2 2025 and -$46.6 million for Q1 2025.